Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
Abstract
This study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options. SURVEYOR-II, Part 3 was …
Keywords
hepatitis c
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
adult
female
male
aged
middle aged
Clinical Trial
Phase III
Randomized Controlled Trial
Multicenter Study
Genotype
chronic / blood
drug therapy
combination
chronic / complications
chronic / virology
chronic / drug therapy*
alanine transaminase / blood
antiviral agents / administration & dosage*
fred poordad
sustained virologic response
Quinoxalines / adverse effects
benzimidazoles / administration & dosage*
federico j mensa
benzimidazoles / adverse effects
quinoxalines / administration & dosage*
sulfonamides / administration & dosage*
sulfonamides / adverse effects
pmid:28926120
pmc5817409
doi:10.1002/hep.29541
david wyles
liver cirrhosis / etiology*
Access
Citation
ID:
268897
Ref Key:
d2018hepatologyglecaprevir/pibrentasvir
Use this key to autocite in
SciMatic or
Thesis Manager
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
268897
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet